Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYinqiang ZhangLLLin LiuGuangdong Pharmaceutical University

Discussion

Loading...

Member takes

Implication

Bridging therapy with glofitamab enhances response rates in high-risk non-Hodgkin lymphoma, suggesting it may redefine treatment paradigms.

Key Points

  • Overall response rate was 66.7%, with 80% of patients achieving complete metabolic response after CAR-T infusion.
  • Patients with high-risk NHL received glofitamab before CD19 CAR-T therapy, assessing safety and efficacy.
  • Assessment of response used Lugano criteria, and adverse events monitored by established therapy guidelines.
  • Results support further validation of glofitamab's bridging role in CAR-T therapy for non-Hodgkin lymphoma.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6b7https://doi.org/10.1182/blood-2025-7261
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025
  2. 2Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  3. 3Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations